Short Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 50.5%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 10,800 shares, a drop of 50.5% from the December 31st total of 21,800 shares. Based on an average trading volume of 309,200 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.6% of the shares of the company are short sold.

Apollomics Stock Performance

NASDAQ:APLM traded down $0.41 during mid-day trading on Thursday, hitting $8.70. 18,706 shares of the stock were exchanged, compared to its average volume of 19,862. The firm’s 50-day simple moving average is $9.51 and its 200 day simple moving average is $12.82. Apollomics has a fifty-two week low of $6.50 and a fifty-two week high of $85.00.

Institutional Trading of Apollomics

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC boosted its position in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the period. Exchange Traded Concepts LLC owned 1.41% of Apollomics worth $179,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.